Update in Asthma 2009

摘要: The emergence of a novel H1N1 influenza virus in early 2009 dominated the headlines and caused much fear worldwide as Centers for Disease Control (CDC) proclaimed pandemic (1). media's preoccupation with epidemic, however, meant less “on-air” time debates on safety asthma medications, focus last year's update (2). Ironically, clinical trials this year also shifted away from usual medications toward use alternative “nonasthma” to treat comorbidities (3, 4) or immunomodulators (5) goal improved control (decreased impairment). importance exacerbations marker poor risk factor long-term outcomes was investigated (6). Other studies examined prediction effective treatment (7, 8). Challenges severe were explored (9) monoclonal antibodies studied (10–12) potential options patients most disease. Articles published American Journal Respiratory Critical Care Medicine advanced our understanding influence genetics (13–20), gene regulation (19, 21–23), factors life (24–28), environment (24, 29–33) development modification disease severity. Basic pathobiological humans (22, 23, 30, 34–44) animals (21, 29, 36, 45–56) added specific mechanisms different phenotypes asthma. Overall, few areas emerge particular highlights we your attention topics below.